PTO/SB/21 (04-04) Approved for use through 07/31/2006. OMB 0651-0031

		U. S. Patent and Trade	mark Office; U.S	. DEPARTMENT OF COMMERCE		
PE	Application Number	10/690,118				
mak " Torre		Filing Date	October 21,	2003		
		First Named Inventor	Albaneze-W	alker, et al		
		Art Unit	1625			
(to be see for all correspondence after	initial filing)	Examiner Name	B. Dentz			
Total Number of Pages in This Submission	n 22	Attorney Docket Number	21229Y-2			
	ENCLOSURES	(Check all that app	ly)			
Fee Transmittal Form	Drawing(s)			Allowance Communication anology Center (TC)		
Fee Attached Licensing-relate		ed Papers	Appeal Communication to Boar of Appeals and Interferences			
Amendment/Reply After Final Petition to Conv Provisional App			Appeal	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
Affidavits/declaration(s) Power of Attorn		ney, Revocation respondence Address	``	Proprietary Information		
Extension of Time Request Terminal Discla		•	Status Letter			
Express Abandonment Request Request for Ref		fund	Other Enclosure(s) (please			
☐ Information Disclosure Statement ☐ CD, Number		CD(s)	Identify below):			
Certified Copy of Priority Document(s)	Remarks			, 		
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATI	URE OF APPLICAL	NT, ATTORNEY, OR	AGENT			
Curtis C. Panzer	Curtis C. Panzer		v/Agent)	33,752		
gnature			Date	6/29/2004		
CERT	IFICATE OF TRA	NSMISSION/MAILIN	(G			
I hereby certify that this correspondence Postal Service with sufficient postage as		envelope addressed to:				

Date

June 29, 2004

Typed or printed | Curtis C. Panzer

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



In re application of: ALBANEZE-WALKER, ET AL	
Serial No. 10/690,118	
Filed October 21, 2003	
Group Art Unit 1625	_
Examiner B. Dentz	

For: ONE POT METHOD OF PREAPRING INTERMEDIATES USEFUL IN MAKING OF PHOSPHODIESTERASE-4

Transmitted herewith is an amendment in the above-identified application.

$ \mathbf{X} $	No	additional	fee	is	required.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims remaining after amendment		Highest Number Previously Paid For	Present Extra	Rate	Additional Fee
Total Claims	*	-	** =	x	\$18	=0.00
Independent Claims	*	-	***=	X	\$86	=0.00
Multiple Dependent Claims					\$290 ****	=
		1	TOTAL ADDITIONAL F	EE FOR THIS AMEND	MENT	0.00

- * If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.
- ** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.

 *** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.
- Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ <u>0.00</u>	to Deposit Account	No. 13-2755.	Please charge any	additional fees or credit
overpayment to Deposit Ac	count No. 13-2755.	A duplicate c	opy of this sheet is	enclosed.

Respectfully, Canju
By: Curtis C. Panzer (
Attorney for Applicant(s)
Reg. No. <u>33,752</u>
MERCK & CO., INC. Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732) 594- <u>3199</u>
Date: June 29, 2004

IN DUPLICATE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

.....

Applicant:

Albaneze-Walker et al.

Serial No.:

10/690,118

Case 21229Y-2

Art Unit: 1625

Filed

October 21, 2003

. Examiner: B. Dentz

For

One Pot Method of Preparing intermediates Useful in

Making Inhibitors of Phosphodiesterase-4

Assistant Commissioner for Patents Washington, D.C. 20231

AMENDMENT

This is in response to a non-final Office Action Mailed April 14, 2004, setting forth a shortened statutory period for response ending July 14, 2004. Reconsideration of Applicants claims is requested. Any additional fees required in connection with this amendment may be taken from Merck deposit Account 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.